Another phase I trial covering an evaluation of EPHA2-specific therapy in GBM covered the locoregional administration of interleukin 13 (IL-13) and ephrin A1 (EFNA1)-based bacterial cytotoxins targeted to interleukin 13 receptor subunit alpha 2 (IL13RA2) and EPHA2 receptors to dogs with GBM [122]. This evidence concerns the gene EFNA1 and glioblastoma.